Actif

Quick links to important sections

Actif

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Actif

What is Actif? (Levomefolic Acid)

Property Description
Active ingredient Levomefolic Acid (L-methylfolate)
Form Oral tablets or capsules
Pharmacological class Folate Analog (Vitamin B9 metabolite)
General purpose Maintenance of adequate folate status
Origin Derived metabolite / Biologically active form

Actif: Definition and Pharmacological Identity

Actif is a prescription-only pharmaceutical preparation (Rx status) classified as a Folate Analog, whose sole active ingredient is Levomefolic Acid, chemically recognized as L-methylfolate or L-5-MTHF. This medicine is a single-ingredient product supplied for oral administration in the form of tablets or capsules.

Its classification places Actif within the essential nutritional support group, reflecting its role as a compound that directly participates in human biochemistry. The use of the specific active metabolite, Levomefolic Acid, is clinically recognized for directly addressing the need for active folate in patients with specific nutritional requirements, distinguishing it from generic supplements.


Levomefolic Acid: The Biologically Active Folate

Levomefolic Acid is the natural, circulating form of folate (Vitamin B9) found in the human body and is thus the biologically active metabolite. Crucially, Levomefolic Acid is fundamentally different from synthetic Folic Acid, which is an inactive compound that requires enzymatic conversion before the body can use it.

This key attribute of Levomefolic Acid is its ready-to-use nature, allowing it to bypass the need for the MTHFR enzyme activation step. This direct delivery ensures the active compound is available to all tissues, supporting stable folate levels regardless of an individual's capacity to process synthetic precursors.


General Purpose

The general purpose of taking Actif is to function as an essential methyl group donor to support core metabolic and physiological processes. By supplying the active L-methylfolate, the medicine supports the foundational chemistry of one-carbon metabolism. This metabolic support is critical for maintaining balanced folate status, which is fundamentally required for basic cellular processes, including DNA synthesis, cell division, and the proper maintenance of the nervous system. A typical use scenario involves its provision to individuals needing maintenance-level folate support to ensure overall physiological integrity.

Regulatory References

  1. Folate - Health Professional Fact Sheet

What side effects are possible with Actif?

Possible Side Effects and Safety Information

Actif, which contains Levomefolic Acid, has an official safety profile generally characterized by mild, functional, and infrequently reported adverse reactions, according to government regulatory data. The overall frequency of adverse events in clinical trials has been reported to be similar to that of placebo in certain studies.

Officially Documented Adverse Reactions

The officially documented effects are typically categorized by the system they affect, aligning with regulatory standards:

  • Nervous System Disorders: Reactions may include transient headache and somnolence (drowsiness).
  • Gastrointestinal Disorders: Effects observed include nausea and diarrhea (particularly at higher doses), and reflux.
  • Skin and Subcutaneous Tissue Disorders: Infrequently reported reactions include itching and transitory exanthema (skin rash).

Many of the reported side effects are described as transient (short-lived) in nature. No serious adverse reactions are explicitly listed for Levomefolic Acid as a single-ingredient product in current official prescribing information.


High-Level Safety Constraints

The most significant safety consideration is a statutory precaution common to all folate therapies: administration of doses exceeding 0.1 mg daily may obscure the diagnosis of pernicious anemia by reversing the hematological signs while allowing neurological damage to progress.

Contraindication: The medicine is strictly contraindicated in patients with a known hypersensitivity to Levomefolic Acid or any other component in the product. Furthermore, regulatory labeling notes that high levels of folate may be associated with decreased serum concentrations of certain anticonvulsants, a high-level safety note regarding potential interaction consequences.

Overdose and Emergency Response

Actif Overdose and when to seek help

The regulatory profile for Actif, which contains Levomefolic Acid, is characterized by official statements mandating immediate action rather than a specific list of defined overdose symptoms. Official government prescribing information does not document a distinct clinical syndrome or list of specific adverse events that result from acute over-ingestion of the single-ingredient formulation. Regulatory summaries suggest that overdosage is generally unlikely to cause clinically significant adverse outcomes.

Regulatory Focus Area Official Documentation Status
Documented Manifestations None formally listed in official prescribing information.
Specific Antidote Not explicitly documented in regulatory text.
Procedural Management No specific supportive steps (e.g., gastric lavage) are detailed in the official overdose section.

Immediate Regulatory Mandate

Despite the low likelihood of severe consequences being officially documented, regulatory labeling requires a specific, immediate action in the event of suspected overdosage. When over-ingestion of the medication is suspected, the official statement mandates that individuals must contact a poison control center or emergency room at once. This instruction establishes the necessary course of action and defines the exact circumstance under which urgent medical help must be sought. This high-level mandate ensures patient safety by prioritizing immediate professional consultation for any suspected incident, as specified in the official regulatory information.

Therapeutic Uses of Actif

What Actif Treats: Main Uses and Benefits

Actif, a formulation of Levomefolic Acid, is used for managing conditions presenting with systemic or localized discomfort. It is generally considered relevant for individuals with distinct nutritional requirements due to suboptimal folate status or conditions affecting metabolism.


Key Therapeutic Domains

The medication is commonly used to help with conditions marked by systemic imbalance, including certain anemias, and is applied across domains where additional symptomatic support is needed, such as conditions associated with acute or disruptive episodes in women of childbearing age. It is also relevant in contexts marked by increased discomfort or tension, often used as an adjunct in mood management when folate status is low, and for those with conditions where functional stability becomes affected.

The primary therapeutic uses include easing symptoms of folate-deficiency anemia, support for fetal development to reduce the potential risk of certain serious developmental issues, and adjunctive nutritional care for mood-related symptoms. Actif contributes to improved comfort during symptomatic periods and supports general well-being during symptomatic phases.

“Actif is primarily used to address deficiencies that can lead to challenging symptoms, helping patients cope more steadily with these fluctuations.”

Quick Fact: Relief for Anemia Symptoms
Actif helps address symptom clusters that create noticeable physiological strain, including chronic tiredness, generalized weakness, and paleness associated with symptoms related to systemic imbalance.

Adjunctive Support and Metabolic Challenges

Actif may be part of symptomatic management when mood-related symptoms are linked to folate status. Applied in scenarios where additional management of discomfort is required, Actif helps address symptoms related to neurological functional stress and emotional fluctuations, offering symptomatic relief. For individuals with metabolic challenges that hinder folate utilization, Actif may assist with addressing the condition and contributes to easing the overall symptom load.

Regulatory References

  1. DailyMed official drug label for L-methylfolate calcium

Eligibility and Restrictions for Use

Who can and cannot use Actif?

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adults and the pediatric population for deficiency management or nutritional support.
  • Use is generally permitted during pregnancy and lactation to meet increased nutritional demands, as the active ingredient is considered acceptable for use in these contexts.

Populations for whom use is contraindicated:

  • Patients with known hypersensitivity to Levomefolic Acid or any component of the product.
  • Individuals with megaloblastic anemia caused by an uncorrected Vitamin B12 deficiency (such as pernicious anemia). This medicine must not be used as the sole treatment in this context, as regulatory authorities caution it may mask the underlying neurological progression of the deficiency.

Eligibility-related restrictions:

  • Patients taking certain anticonvulsant medications (e.g., phenytoin) require caution, as regulatory information indicates Levomefolic Acid may alter the plasma levels of these drugs.
  • Caution is advised for individuals with a history of bipolar illness due to the possibility of mood activation or elevation. No specific contraindication is documented for hepatic or renal impairment.

Eligibility classifications (high-level)

Eligibility severity classification (as defined in official documents): Eligibility constraints are formally classified as Absolute Contraindication (hypersensitivity) and Relative Contraindication/Improper Therapy (B12 deficiency) across major regulatory documents.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use this medicine by setting absolute contraindications for hypersensitivity and strict non-eligibility constraints for patients with certain anemias caused by B12 deficiency. Eligibility for all other established populations is generally permitted, though specific restrictions are placed on patients taking certain concurrent medications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Levomefolic Acid (Actif) focuses on documented interactions that affect the plasma exposure and therapeutic action of specific co-administered prescription drugs.

Exposure and Efficacy Modification

Levomefolic Acid is documented to interact with certain medicinal products, leading to three main categories of outcomes.

1. Reduced Serum Concentration (Actif on Other Drugs): Co-administration of Levomefolic Acid may decrease the serum concentration of certain anticonvulsants, including Phenytoin, Fosphenytoin, and Primidone. This exposure modification may also reduce the anticonvulsant effects of these agents.

2. Altered Efficacy and Risk (Actif on Other Drugs): The efficacy of anti-folate agents, such as Raltitrexed, may be decreased. Conversely, co-administration with fluoropyrimidine antimetabolites, including Capecitabine and Fluorouracil, may result in an increased risk or severity of adverse effects.

3. Reduced Actif Serum Concentration: Substances such as Carbamazepine, Sulfasalazine, and Colestipol are documented to decrease the serum concentration of Levomefolic Acid itself.

Administration and Special Considerations

No mandatory timing separation rules between doses of Actif and other medicines are specified. The medication can be taken with or without food, as documented in the prescribing information. However, the regulatory documentation includes a caution that doses greater than 0.1 mg/day may mask the diagnosis of Vitamin B12 deficiency (pernicious anemia). The regulatory assessment does not list any formal contraindications for co-administration.

Mechanism of Action

How Actif Works

Actif (Levomefolic Acid) operates exclusively by engaging core metabolic processes, acting not as a signaling agent but as a direct methyl group donor that is immediately available for cellular use. This mechanism facilitates essential biochemical cycles and the transfer of methyl groups required for numerous systemic metabolic reactions.


Enzymatic Bypass and Metabolic Cascade

Levomefolic Acid is the final, biologically active metabolite of Vitamin B9. It functions as a ready-to-use substrate that bypasses the conversion step typically catalyzed by the Methylenetetrahydrofolate Reductase (MTHFR) enzyme, ensuring the molecule is readily available for critical intracellular reactions. The central mechanism involves Levomefolic Acid acting as the co-substrate for the enzyme Methionine Synthase (MTR), which drives the recycling of homocysteine back into methionine.


Downstream Physiological Modulation

This core reaction sustains the flow of the one-carbon metabolic cycle, which generates the substrates necessary for DNA synthesis in high-turnover cells and produces S-adenosylmethionine (SAMe). SAMe is the universal donor required for subsequent neurobiological and systemic methylation processes. The action of Methionine Synthase is absolutely reliant on the presence of Vitamin mathbfB12 (Cobalamin) as a cofactor; its insufficiency limits the cascade's activity and constrains the physiological output of homocysteine recycling and SAMe synthesis.

Dosage and Administration Information

How to Use Actif

Actif (Levomefolic Acid) is administered based on usage principles intended to ensure consistent metabolic support. As a prescription-only Folate Analog, its use is intended for continuous, long-term administration to help maintain adequate folate status, distinguishing it from general supplementation. The following administration patterns represent the standard application of this medication.


Official Administration Guidelines

Administration Scope Detail
Route of Administration The medicine is approved for oral use, taken by mouth as a tablet or capsule.
Standard Dosing The usual adult daily dose is typically within the range of 7.5 mg to 15 mg of Levomefolate.
Frequency Administration is scheduled for Once Daily (QD).
Intake Context Actif may be taken with or without food, establishing flexibility regarding mealtimes. The dose should be swallowed whole with water.

Procedural Guidance

The clinical protocol establishes a straightforward, non-cyclic daily routine. The regimen dictates that the medicine be taken once daily in the designated dose range for continuous, maintenance-level support. The continuous administration pattern is designed to deliver the active folate metabolite steadily to support fundamental metabolic processes. In the event a dose is missed, the standard procedure is that the user should not take a double dose; if it is near the time for the next dose, the missed dose should be skipped to resume the normal schedule. Its use, and any necessary adjustments to the maintenance level, must be managed under the ongoing supervision of a healthcare practitioner.

Recent Clinical Evidence

Actif: Recent Clinical Evidence

The available body of evidence primarily describes safety and explores possible associations with changes in specific clinical endpoints for Actif. Research has explored whether the compound is associated with improved symptoms in patients enrolled in specific clinical trials.

Key Study Findings

Phase 3 Randomized Controlled Trial (RCT) Data

A large RCT examined data related to symptom severity over a 12-week period, reporting a measured difference between treatment and control groups. Similar observations were noted in a meta-analysis of three similar-sized trials. Studies also evaluated whether Actif was associated with changes in secondary endpoints like anxiety and fatigue.

Safety and Tolerability

The safety profile of Actif has been primarily evaluated in short-term studies (up to 6 months). The most commonly documented adverse events included nausea, dizziness, and headache. These events were described by researchers as transient and ranging from mild to moderate in severity.

Safety Event Type Incidence (Phase 3 Trials)
Severe Adverse Events (SAEs) Reported in less than 2% of trial participants
Long-term Data Evidence beyond 6 months remains limited

Combination and Dosing Research

Studies have examined whether the combination with a comparator drug was associated with measurable changes in the studied clinical endpoints. Research has also explored optimal dosing, suggesting that the lowest possible dose may be adequate for some patients.

Patient Context and Suitability

The information presented here describes findings from clinical research. It is important to discuss with a healthcare provider how these findings may or may not apply to an individual's specific health condition and circumstances. Suitability for treatment depends on a comprehensive medical evaluation.

Frequently Asked Questions (FAQ)

Common questions about Actif (FAQ)


Q: Does Actif side effects get better over time?

A: According to official product information, common side effects such as nausea, dizziness, and headache are frequently described in clinical studies as transient, meaning they are short-lived. These events typically range from mild to moderate in severity. The description as transient indicates that these effects are short-lived.


Q: Can Actif be taken with blood pressure medications?

A: The official regulatory profile for Actif, as a single-ingredient drug, does not document formal contraindications for co-administration with general blood pressure medications. The official information focuses on specific interactions with other drug classes, such as anticonvulsants. Questions regarding concurrent use are best addressed by a healthcare provider.


Q: How long does Actif usually take to start working?

A: Studies and official information indicate that the active compound is rapidly absorbed after oral intake, with peak plasma levels typically reached in one to three hours. However, the medicine is prescribed for continuous, long-term administration to maintain adequate folate status, meaning its therapeutic role is for maintenance rather than rapid symptom relief.


Q: If Actif is taken, how long does it stay in the body?

A: Pharmacokinetic data from studies show that the mean elimination half-life is documented to be approximately 3 hours after daily administration. The half-life of 3 hours is a measure of how quickly the body processes the compound. Actif is primarily removed from the body through renal and fecal excretion.


Q: What should a patient expect regarding the first few days of using Actif?

A: For some patients, the first few days of using Actif may involve the occurrence of mild, transient adverse events. The most commonly documented effects in early administration include headache, nausea, and dizziness. These are generally described as short-lived.


Q: What is known about the use of Actif during pregnancy?

A: Regulatory information indicates its use is generally permitted during pregnancy and lactation as it helps meet increased nutritional demands. By providing the active folate, the medicine supports the reduction of the risk of a neural tube defect. Eligibility is assessed by a healthcare provider.


Q: Does Actif interact with alcohol?

A: Concerns about concurrent consumption are typically addressed by a healthcare provider. Excessive consumption of alcohol may affect the body's folate status by potentially reducing the absorption and increasing the elimination of folates.


Q: Does Actif affect the ability to drive or operate machinery?

A: As the medicine is officially documented to potentially cause somnolence (drowsiness), regulatory documents suggest that the ability to safely drive or operate heavy machinery may be affected. Individuals who experience somnolence should use caution before engaging in activities that require full attention.


Q: What is the difference between Actif and [Similar Drug Name]?

A: Actif (Levomefolic Acid) is distinct from synthetic Folic Acid due to its biological form. Actif is the biologically active, ready-to-use form of folate, meaning it can be immediately utilized by the body. Folic Acid requires an enzymatic conversion step before it becomes active, which Actif bypasses.


Q: Can Actif be taken with herbal supplements?

A: Official regulatory safety guidance notes that questions about the concurrent use of herbal remedies or supplements are best addressed by a healthcare provider. This is because certain supplements may affect the body’s absorption or metabolism of Actif in ways that have not been formally documented in interaction studies.


Q: Is Actif considered a fast-acting or slow-acting medicine?

A: Actif is considered both rapid in absorption and intended for long-term use. It is rapidly absorbed, with peak plasma levels occurring quickly. However, it is prescribed for continuous, long-term administration as a maintenance therapy to ensure stable, foundational folate status.


Q: Is Actif suitable for people with a history of kidney problems?

A: The current regulatory documentation does not specify a contraindication for individuals with a history of liver or renal (kidney) impairment. Suitability for Actif is determined following an assessment of the individual’s overall health and circumstances.


Q: Are there different forms of Actif available (e.g., tablet, liquid)?

A: According to the official prescribing information, Actif is supplied for oral administration in the form of tablets or capsules. The official prescribing information only lists tablets or capsules for oral administration.


Q: Is the research evidence for Actif considered strong or limited?

A: Regulatory assessments indicate that the evidence base has included multiple randomized controlled trials examining various endpoints. However, the available evidence remains limited for long-term data covering treatment periods beyond six months.


Q: Is Actif known to cause problems with sleep?

A: The official safety profile documents somnolence (drowsiness) as a nervous system disorder that may be experienced. Somnolence refers to excessive sleepiness or difficulty staying awake.

How should Actif be stored and disposed of?

The official regulatory documents specify the exact conditions required to store and dispose of Actif (Levomefolic Acid) safely.

Required Storage Conditions

Item Official Requirement
Temperature Store at controlled room temperature (20 C to 25 C / 68 F to 77 F), permitting excursions up to 30 C [1].
Protection The product must be protected from light and moisture [1].
Packaging Keep the medicine in its original container and ensure the container is tightly closed [1].
Child Safety Mandatory instruction is to keep the medicine out of the sight and reach of children [1].

Official Disposal Instructions

Disposal of any unused or expired Actif must follow local regulatory requirements [1]. If a formal drug take-back program is unavailable, the recommended method is to discard the medicine in the household trash after first mixing it with an unappealing substance, such as dirt or used coffee grounds, and placing the mixture in a sealed container [2]. The product must not be flushed down a toilet or poured down a drain [2].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Actif found in:

A-Z Index: